Evidence map›Paper›PMID 29725943›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2018

In Vitro Monitoring of the Mitochondrial Beta-Oxidation Flux of Palmitic Acid and Investigation of Its Pharmacological Alteration by Therapeutics.

Renata Murgasova, Ester Tor Carreras, Julien Bourgailh

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Renata MurgasovaPKS, Novartis Institute for Biomedical Research, Novartis Pharma AG, WSJ-153.1.16, 4002, Basel, Switzerland. renata.murgasova@novartis.com.
Ester Tor CarrerasPKS, Novartis Institute for Biomedical Research, Novartis Pharma AG, WSJ-153.1.16, 4002, Basel, Switzerland.
Julien BourgailhPKS, Novartis Institute for Biomedical Research, Novartis Pharma AG, WSJ-153.1.16, 4002, Basel, Switzerland.
Novartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe present study was designed to validate the functional assay that enables rapid screening of therapeutic candidates for their effect on mitochondrial fatty acid oxidation.

methodsThe two whole-cell systems (tissue homogenates and hepatocytes) have been evaluated to monitor the total beta-oxidation flux of physiologically important

resultsOur results with several known inhibitors of fatty acid oxidation showed that this simple assay could correctly predict a potential in alteration of mitochondrial function by drug candidates. Since the beta-oxidation of palmitic acid takes place almost exclusively in mitochondria of human hepatocytes, this model can be also utilized to distinguish between the mitochondrial and peroxisomal routes of this essential metabolic pathway in some cases.

conclusionsThe present work offers a new in vitro screen of changes in mitochondrial beta-oxidation by xenobiotics as well as a model to study the mechanism of this pathway.

Indexed as

AnimalsCells, CulturedDose-Response Relationship, DrugDrug DiscoveryEnzyme InhibitorsFatty AcidsHepatocytesHumansLiverLungMaleMitochondriaOxidation-ReductionPalmitic AcidRatsTritiumEnzyme InhibitorsFatty AcidsPalmitic AcidTritium

Identifiers

PMID29725943
OpenAlexW2800717899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.